Drug Alerts and Special Reports

Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.

Subscribe To Newsletter

J-Code 04/10/2023

Permanent HCPCS J-Code for SPEVIGO - 3/27/23

Permanent HCPCS J-Code for SPEVIGO EFFECTIVE APRIL 1, 2023 A monoclonal IgG1 antibody for the treatment of generalized pustular psoriasis (GPP) flares in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SPEVIGO is contraindicated in patients with severe or life-threatening hypersensitivity to spesolimabsbzo or to any of the excipients in SPEVIGO. Reactions have included drug reaction with eosinophilia and systemic symptoms (DRESS). Please see additional Important Safety Information below and full Prescribing Information , including Medication Guide . Coding for SPEVIGO* Code Type Code Description ICD-10-CM L40.1 Generalized pustular psoriasis CPT 96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour 96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) HCPCS J Code J1747 Injection…

04/10/2023

New HCPCS Code Descriptor for J1954 Cipla USA's LEUPROLIDE ACETATE INJECTION DEPOT - 3/14/23

Effective April 1, 2023: New HCPCS Code Descript or for J1954: Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg. J1954 is a unique HCPCS code for Cipla's version of LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) and sh ould not be used for billing other leuprolide formulations. HCPCS Code HCPCS Code Descriptor NDC Number Strength WAC Per Package HCPCS Units Per Package J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg 69097-0909-50 22.5 mg $1,355.07 3 We respectfully request the update of all claims and reimbursement systems to include the new HCPCS code descriptor for J1954: Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg. effective April 1, 2023 Please contact us @ [email protected] © Copyright 2023 Cipla USA Inc. All rights reserved April 2023…

FDA Approved 03/10/2023

Now Approved: SYFOVRE (pegcetacoplan injection) - 3/2/23

Now Approved: SYFOVRE™ (pegcetacoplan injection) Email content sponsored by Apellis Pharmaceuticals, Inc. Email content sponsored by Apellis Pharmaceuticals, Inc. NOW APPROVED: The first and only treatment proven to slow lesion growth rate in GA secondary to AMD 1 SYFOVRE (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) SELECT SAFETY INFORMATION SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with…

Now Available 03/10/2023

Now Available: Orenitram Titration Kits for Simplified Dosing - 3/1/23

Now Available: Orenitram® Titration Kits for Simplified Dosing Orenitram Titration Kits for Simplified Dosing 96 --> Orenitram Titration Kits for Simplified Dosing We are pleased to announce the availability of the Orenitram Titration Kit , designed to simplify dosing and titration so patients can reach the target dose prescribed by their healthcare provider. *De novo patients who are starting Orenitram on a TID dosing schedule are eligible for the Titration Kit. Restrictions apply. 3 MONTHLY KITS 4 WEEKLY BOXES PER MONTH 7…

Pricing 03/10/2023

Price Change for HEPLISAV-B, Hepatitis B Vaccine (Recombinant) - 2/23/23

Announcing a price change for HEPLISAV-B®, {Hepatitis B Vaccine (Recombinant), Adjuvanted} This message is being sent by www.BuyandBill.com on behalf of Dynavax Technologies Effective March 1, 2023 the pricing of HEPLISAV-B ® will change as outlined below. Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. HEPLISAV-B® NDC Code and Pricing: CPT Code 11 Digit NDC Code Effective Date Product Description WAC Per Package WAC Per Syringe Estimated AWP…

03/10/2023

Lamzede: New Treatment Option Available For Ultra-rare LSD - 2/22/23

New Treatment Option Available For Ultra-rare LSD We are pleased to announce the recent FDA approval of Lamzede® (velmanase alfa-tycv); a recombinant human lysosomal alpha-mannosidase indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.1 AM patients have waited a long time for a treatment option and Chiesi is proud to have it now available for them. Dosage and administration: The recommended dosage is 1mg/kg (actual body weight) administered once every week as an…

03/10/2023

J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G - 2/1/23

To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective "> J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) From: BuyandBill.com < [email protected] > To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective January 1, 2023: J1932…

03/09/2023

J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care - 1/4/23

Effective January 1, 2023: J1954 The unique HCPCS code for Cipla USA's LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) Effective January 1, 2023: J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care. J1954 is a unique HCPCS code for Cipla's version of LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) and sh ould not be used for billing other leuprolide formulations. HCPCS Code HCPCS Code Descriptor NDC Number Strength WAC Per Package HCPCS Units Per…

03/08/2023

New Indication for Adcetris J9042 - 1/3/23

Announcing a new approval for pediatric patients 2 years and older with previously untreated high risk classical Hodgkin Lymphoma 96 96 Important Safety Information Prescribing Information ADCETRIS ® (brentuximab vedotin) for injection is now approved for use in pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide. 1 Indication and Recommended Dosage ADCETRIS is a CD30-directed antibody-drug…

02/14/2023

Teva Products: Updated HCPCS Coding Information - 12/19/22

Teva Products: Updated HCPCS Coding Information Updated HCPCS* Coding Information for Teva Products Effective January 1, 2023, providers should use the new, permanently assigned HCPCS codes for these products, as shown in the tables below. Old/temporary HCPCS codes should not be used after December 31, 2022. Please update your claims processing system and any applicable coverage policies and fee schedules. † Fosaprepitant for Injection…

1 … 141516 17

No alerts match your filters.